Share-based Payment Arrangement, Expense of SUPERNUS PHARMACEUTICALS, INC. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
SUPERNUS PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • SUPERNUS PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $30,745,000, a 301% increase year-over-year.
  • SUPERNUS PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $53,952,000, a 103% increase year-over-year.
  • SUPERNUS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $27,755,000, a 3.7% increase from 2023.
  • SUPERNUS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $26,759,000, a 52% increase from 2022.
  • SUPERNUS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $17,568,000, a 1.9% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

SUPERNUS PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $53,952,000 $30,745,000 +$23,071,000 +301% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $30,881,000 $7,507,000 +$955,000 +15% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $29,926,000 $8,068,000 +$2,171,000 +37% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $27,755,000 $7,632,000 +$1,187,000 +18% 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q3 2024 $26,568,000 $7,674,000 -$246,000 -3.1% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $26,814,000 $6,552,000 +$464,000 +7.6% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $26,350,000 $5,897,000 -$409,000 -6.5% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $26,759,000 $6,445,000 +$2,184,000 +51% 01 Oct 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $24,575,000 $7,920,000 +$2,935,000 +59% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $21,640,000 $6,088,000 +$1,791,000 +42% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $19,849,000 $6,306,000 +$2,281,000 +57% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $17,568,000 $4,261,000 +$225,000 +5.6% 01 Oct 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
Q3 2022 $17,343,000 $4,985,000 +$958,000 +24% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $16,385,000 $4,297,000 -$1,179,000 -22% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $17,564,000 $4,025,000 -$346,000 -7.9% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $17,910,000 $4,036,000 +$915,000 +29% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $16,995,000 $4,027,000 -$463,000 -10% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $17,458,000 $5,476,000 +$514,000 +10% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $16,944,000 $4,371,000 +$383,000 +9.6% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $16,561,000 $3,121,000 -$502,000 -14% 01 Oct 2020 31 Dec 2020 10-K 09 Mar 2023 2022 FY
Q3 2020 $17,063,000 $4,490,000 +$576,000 +15% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $16,487,000 $4,962,000 +$940,000 +23% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $15,547,000 $3,988,000 +$701,000 +21% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $14,846,000 $3,623,000 +$632,000 +21% 01 Oct 2019 31 Dec 2019 10-K 13 Apr 2022 2021 FY
Q3 2019 $14,214,000 $3,914,000 +$1,317,000 +51% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 $12,897,000 $4,022,000 +$954,000 +31% 01 Apr 2019 30 Jun 2019 10-Q 17 Aug 2020 2020 Q2
Q1 2019 $11,943,000 $3,287,000 +$652,000 +25% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q4 2018 $11,291,000 $2,991,000 +$1,005,000 +51% 01 Oct 2018 31 Dec 2018 10-K 08 Mar 2021 2020 FY
Q3 2018 $10,286,000 $2,597,000 +$237,000 +10% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $10,049,000 $3,068,000 +$808,000 +36% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $9,241,000 $2,635,000 +$808,000 +44% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $8,433,000 $1,986,000 +$514,000 +35% 01 Oct 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
Q3 2017 $7,919,000 $2,360,000 +$877,000 +59% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $7,042,000 $2,260,000 +$648,000 +40% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $6,394,000 $1,827,000 +$468,000 +34% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $5,926,000 $1,472,000 +$534,000 +57% 01 Oct 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
Q3 2016 $5,392,000 $1,483,000 +$351,000 +31% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $5,041,000 $1,612,000 +$494,000 +44% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $4,547,000 $1,359,000 +$457,000 +51% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $4,090,000 $938,000 +$206,000 +28% 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
Q3 2015 $3,884,000 $1,132,000 +$326,000 +40% 01 Jul 2015 30 Sep 2015 10-Q 20 Jan 2017 2016 Q3
Q2 2015 $3,558,000 $1,118,000 +$466,000 +71% 01 Apr 2015 30 Jun 2015 10-Q/A 23 Jan 2017 2016 Q2
Q1 2015 $3,092,000 $902,000 +$235,000 +35% 01 Jan 2015 31 Mar 2015 10-Q/A 20 Jan 2017 2016 Q1
Q4 2014 $2,857,000 $732,000 +$79,000 +12% 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
Q3 2014 $2,778,000 $806,000 +$315,000 +64% 01 Jul 2014 30 Sep 2014 10-Q/A 20 Jan 2017 2015 Q3
Q2 2014 $2,463,000 $652,000 +$220,000 +51% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $2,243,000 $667,000 +$330,000 +98% 01 Jan 2014 31 Mar 2014 10-Q 06 May 2015 2015 Q1
Q4 2013 $1,913,000 $653,000 +$446,000 +215% 01 Oct 2013 31 Dec 2013 10-K/A 20 Jan 2017 2015 FY
Q3 2013 $1,467,000 $491,000 +$360,000 +275% 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 $1,107,000 $432,000 +$379,000 +715% 01 Apr 2013 30 Jun 2013 10-Q 12 Aug 2014 2014 Q2
Q1 2013 $728,000 $337,000 +$285,000 +548% 01 Jan 2013 31 Mar 2013 10-Q 13 May 2014 2014 Q1
Q4 2012 $443,000 $207,000 01 Oct 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
Q3 2012 $131,000 01 Jul 2012 30 Sep 2012 10-Q 13 Nov 2013 2013 Q3
Q2 2012 $53,000 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013 2013 Q2
Q1 2012 $52,000 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013 2013 Q1

SUPERNUS PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $27,755,000 +$996,000 +3.7% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
2023 $26,759,000 +$9,191,000 +52% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
2022 $17,568,000 -$342,000 -1.9% 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2021 $17,910,000 +$1,349,000 +8.1% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $16,561,000 +$1,715,000 +12% 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2023 2022 FY
2019 $14,846,000 +$3,555,000 +31% 01 Jan 2019 31 Dec 2019 10-K 13 Apr 2022 2021 FY
2018 $11,291,000 +$2,858,000 +34% 01 Jan 2018 31 Dec 2018 10-K 08 Mar 2021 2020 FY
2017 $8,433,000 +$2,507,000 +42% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
2016 $5,926,000 +$1,836,000 +45% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
2015 $4,090,000 +$1,233,000 +43% 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
2014 $2,857,000 +$944,000 +49% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $1,913,000 +$1,470,000 +332% 01 Jan 2013 31 Dec 2013 10-K/A 20 Jan 2017 2015 FY
2012 $443,000 +$525,000 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
2011 $82,000 -$379,000 -128% 01 Jan 2011 31 Dec 2011 10-K 21 Mar 2014 2013 FY
2010 $297,000 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.